[Comment] Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?

Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?
Affiliations & Notes
aDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, Netherlands
bThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
Article Info
Publication History:
Published June 8, 2026
DOI: 10.1016/S0140-6736(26)01040-8 External LinkAlso available on ScienceDirect External Link
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Download started
OkPharmacotherapy for the treatment of type 2 diabetes has changed profoundly. SGLT2 inhibitors and GLP-1 receptor agonists are now well recognised for their improvements in metabolic control and, importantly, cardiovascular and kidney protective effects.1 As a consequence, the glucose-centric treatment paradigm for individuals living with diabetes has shifted towards a treatment strategy focused on microvascular and macrovascular protection. Early treatment recommendations highlighted the complementary aspects of both drug classes: SGLT2 inhibitors primarily for heart failure and kidney protection; GLP-1 receptor agonists for atherosclerotic cardiovascular disease prevention. Yet, this separation is becoming increasingly inadequate as more recent studies have shown that GLP-1 receptor agonists also improve heart failure symptoms and slow the progression of kidney disease.1 Furthermore, the clinical availability of oral GLP-1 receptor agonists offers an opportunity that has the potential to enhance the adoption of GLP-1 receptor agonist treatment beyond what has been achievable with SGLT2 inhibitors alone. Against this background, the ACHIEVE-2 trial, presented by Michelle Welch and colleagues in The Lancet and comparing head to head the SGLT2 inhibitor dapagliflozin with the oral GLP-1 receptor agonist orforglipron, is of interest.2
References
1.
Brown, E ∙ Heerspink, HJL ∙ Cuthbertson, DJ ∙ et al.
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Lancet. 2021; 398:262-276
2.
Welch, M ∙ Forst, T ∙ Weiping, J ∙ et al.
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
Lancet. 2026;
published online June 8. https://doi.org/10.1016/S0140-6736(26)00800-7
3.
Nauck, MA ∙ Tuttle, KR ∙ Tschöp, MH ∙ et al.
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
Lancet. 2026; 407:892-908
4.
Heerspink, HJ ∙ Perkins, BA ∙ Fitchett, DH ∙ et al.
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
Circulation. 2016; 134:752-772
5.
Powell-Wiley, TM ∙ Poirier, P ∙ Burke, LE ∙ et al.
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Circulation. 2021; 143:e984-1010
6.
Apperloo, EM ∙ Neuen, BL ∙ Fletcher, RA ∙ et al.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Lancet Diabetes Endocrinol. 2024; 12:545-557
7.
Neuen, BL ∙ Fletcher, RA ∙ Heath, L ∙ et al.
Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis
Circulation. 2024; 150:1781-1790
8.
Horn, DB ∙ Aronne, LJ ∙ Wharton, S ∙ et al.
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial
Lancet. 2026;
published online May 12. https://doi.org/10.1016/S0140-6736(26)00656-2

Facts Only

* Oral GLP-1 receptor agonists and SGLT2 inhibitors improve metabolic control and provide cardiovascular and kidney protective effects in type 2 diabetes.
* SGLT2 inhibitors are primarily indicated for heart failure and kidney protection.
* GLP-1 receptor agonists are primarily indicated for atherosclerotic cardiovascular disease prevention.
* Recent studies show GLP-1 receptor agonists also improve heart failure symptoms and slow the progression of kidney disease.
* The ACHIEVE-2 trial compared dapagliflozin and orforglipron in adults with type 2 diabetes and inadequate glycemic control.
* The study presented by Welch and colleagues compared the two drug classes head to head.

Executive Summary

Oral GLP-1 receptor agonists and SGLT2 inhibitors are recognized for cardiovascular and renal protection in type 2 diabetes management, prompting a shift from glucose-centric treatment to microvascular and macrovascular focus. Initially, SGLT2 inhibitors were recommended primarily for heart failure and kidney protection, while GLP-1 receptor agonists were focused on atherosclerotic cardiovascular disease prevention. However, recent research indicates that GLP-1 receptor agonists also offer benefits in heart failure symptom improvement and slowing kidney disease progression. The clinical availability of oral GLP-1 receptor agonists provides an opportunity to expand treatment options beyond SGLT2 inhibitors alone. The ACHIEVE-2 trial investigated the comparative efficacy between dapagliflozin (an SGLT2 inhibitor) and orforglipron (an oral GLP-1 receptor agonist).

Full Take

The narrative presents a shift in therapeutic strategy from managing blood glucose to comprehensive organ protection, recognizing that pharmacological agents address multiple comorbidities simultaneously rather than focusing on a single metric. The core tension lies in whether combining these mechanisms—which target different aspects of pathophysiology (glucose handling versus incretin signaling)—yields synergistic benefits beyond what is seen when using either class in isolation. The introduction of oral GLP-1 receptor agonists addresses the clinical gap created by limitations in SGLT2 inhibitor monotherapy, suggesting an evolving understanding that single-target approaches may be insufficient for managing complex diabetic complications. The pattern detected is a systemic evolution driven by multi-organ pathophysiology recognition, where incremental evidence is building toward integrated treatment paradigms rather than strict segregation of indications.
Bridge Questions: What are the specific mechanistic overlaps, if any, between SGLT2 inhibition and GLP-1 agonism in renal or cardiac outcomes? How should clinical guidelines evolve to integrate these dual benefits without creating unnecessary complexity for patients? Does the feasibility of oral GLP-1 agonists represent a fundamental reclassification of diabetes management goals?

Sentinel — Human

Confidence

This text functions as a highly competent, evidence-based summary of evolving pharmacological treatments for diabetes, employing sophisticated synthesis across multiple scientific domains.

Signals Detected

Moderate sentence length variance; academic yet flows logically.

High internal logic; effectively synthesizes complex, multi-source medical concepts without emotional appeal.

Excellent structure linking previous established knowledge (SGLT2 vs GLP-1) to emerging clinical gaps and a specific trial (ACHIEVE-2).

References appear plausible and contextually appropriate for medical literature; no obvious LLM confabulation detected.

Human Indicators

The structure is highly specialized, weaving together established consensus (SGLT2/GLP-1 roles) with cutting-edge trial data (ACHIEVE-2), which requires deep domain expertise to synthesize effectively.

The use of citations and the focused argumentation around a specific clinical question suggests grounding in peer-reviewed literature rather than broad generative synthesis.